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Therapeutic Strategies in Huntington’s Disease
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This article provides an overview of the therapeutic strategies, from ordinary classical drugs to the modern 
molecular strategy at experimental level, for Huntington’s disease. The disease is characterized by choreic 
movements, psychiatric disorders, striatal atrophy with selective small neuronal loss, and autosomal dominant 
inheritance. The genetic abnormality is CAG expansion in huntingtin gene. Mutant huntingtin with abnormally long 
glutamine stretch aggregates and forms intranuclear inclusions. In this review, I summarize the results of previous 
trials from the following aspects; 1. symptomatic/palliative therapies including drugs, stereotaxic surgery and 
repetitive transcranial magnetic stimulation, 2. anti-degenerative therapies including anti-excitotoxicity, reversal of 
mitochondrial dysfunction and anti-apoptosis, 3. restorative/reparative therapies including neural trophic factors and 
tissue or stem cell transplantation, and 4. molecular targets in specific and radical therapies including inhibition of 
truncation of huntingtin, inhibition of aggregate formation, normalization of transcriptional dysregulation, enhancement 
of autophagic clearance of mutant huntingtin, and specific inhibition of huntingtin expression by sRNAi. Although the 
strategies mentioned in the latter two categories are mostly at laboratory level at present, we are pleased that one 
can discuss such “therapeutic strategies”, a matter absolutely impossible before the causal gene of Huntington’s 
disease was identified more than 10 years ago. It is also true, however, that some of the “therapeutic strategies” 
mentioned here would be found difficult to implement and abandoned in the future.
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INTRODUCTION
Huntington’s disease (HD) is an adult-onset, chronic 
and progressive neurodegenerative disease. It is 
clinically characterized by abnormal choreic involuntary 
movements and by psychiatric, psychological and 
intellectual disorders, and radiologically characterized by 
striatal atrophy of variable degree. Pathologically, in 
atrophied striatum, the normally predominant small 
projecting neurons are specifically affected. Since these 
neurons are inhibitory in function, whose long axons 
terminate in the substantia nigra and use γ-aminobutyric 
acid (GABA) as a neurotransmitter, GABA levels in the 
substantia nigra of HD are markedly low.
1 On the other 
hand, dopaminergic nigral neurons remain intact in HD 
and, indeed, the dopamine level in the HD striatum is 
higher than normal.
2 Therefore, HD is regarded as a 
relatively dopamine-predominant disease. In agreement 
with this finding, anti-dopaminergic drugs are clinically 
effective against choreic movements. 
Genetically, HD is an autosomal-dominantly inherited Journal of Clinical Neurology: Vol. 2, No. 4, 2006
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disease. Genetic linkage analysis using DNA fragment as 
gene marker revealed in 1983 that HD gene may be 
located at the tip of the short arm of chromosome 4.
3 
Ten years later, the causal HD gene was finally 
identified as IT15, which has CAG repeats in the open 
reading frame (ORF, exactly, in exon 1) just following 
the 5’end of the gene.
4 Since CAG is a codon 
corresponding to glutamine, the gene product, huntingtin, 
should have glutamine stretch or chain. Although the 
function of the normal huntingtin is not fully elucidated, 
the abnormally long glutamine chain in the mutant 
huntingtin distorts the third structure of huntingtin 
protein. Furthermore, these structurally abnormal 
proteins tend to aggregate and to form inclusion bodies 
inside neurons or nuclei.
5 In addition, mutant huntingtin 
may be toxic to functionally important proteins in 
neurons.
6
The progress in medical research particularly from the 
molecular aspect of HD is extremely rapid and 
promising. Although the clinical application is still far 
from reality, cell therapy or gene therapy of HD are no 
longer in the dream but actually a reality in laboratories 
around the world at present. It is relevant, therefore, to 
summarize the progresses particularly in therapeutic 
approaches to HD.
Symptomatic/palliative therapies for HD
1. Drugs that reduce choreic movements and psychiatric 
disorders mostly based on classical theories
Since Thomas Perry and his group in Canada reported 
that HD was a deficiency of GABA in the basal 
ganglia,
1 clinically available drugs related to GABA 
were used in patients to establish their possible 
anti-choreic effects. However, none was found to be 
definitely effective against choreic movements.
7-11 
Based on a recent theory on the mechanism of choreic 
movements involving hyperactivity of the cortico-striatal 
glutamatergic pathways, one of the NMDA-receptor 
antagonists, amantadine was clinically evaluated, but no 
positive effects were confirmed following oral admini-
stration.
12
In contrast to the above mentioned rather dis-
appointing results mostly obtained in theoretically 
supported clinical trials, antipsychotic or dopamine- 
depleting drugs were confirmed largely in 1970’s
13 to be 
effective not only for choreic movements but also for 
psychiatric disorders associated with HD. Later, this was 
found to coincide well with the relatively dominant 
dopamine compared with other neurotransmitters in HD 
striatum.
2 Attention has recently focused on the anti- 
choreic effects of tetrabenazine, which selectively 
depletes monoamines by reversibly binding to the 
type 2 vesicular monoamine transporter.
14
A double-blind, randomized, placebo-controlled 
clinical study of ethyl-eicosa-pentaenoic acid (ethyl- 
EPA) on choreic movements of HD revealed that 
this agent exerts subtle beneficial effects on motor 
dysfunction of HD.
15 Since adverse events of ethyl- 
EPA were negligible, the potential use of ethyl-EPA 
in HD is warranted. 
2. Stereotaxic surgery for choreic movements
Stereotaxic surgery is rarely used in HD. The target 
is the internal segment of the globus pallidus,
16 which is 
the origin of the final common path; ansa lenticularis. 
Usually the outcome is not disappointing, though it is 
rather transient because the disease is highly progressive. 
3. Repetitive transcranial magnetic stimulation (rTMS)
A beneficial effect of rTMS on HD-related choreic 
movements was first proposed by an Italian group in 
1994.
17 However, although small scale investigation 
was carried out,
18 only little information is available 
about the effects of rTMS in HD. Moreover, the 
mechanism of action of rTMS, if any, is not clear at 
present.
Anti-degenerative therapies for HD
1. Anti-excitotoxicity therapyIchiro Kanazawa, Therapeutic Strategies in Huntington’s Disease 
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Based on the excitotonic theory of striatal neuronal 
degeneration in HD, clinically available anti-excitotoxic 
drugs such as amantadine, memantine and riluzole, were 
used in HD patients to suppress choreic movements. 
Although riluzole (which reduces striatal glutamate 
release) was reported to ameliorate the intensity of 
choreic movements,
19 there is no strong clinical evidence 
to support the hypothesis.
2. Reversal of mitochondrial dysfunction
Although the debate on the relationship between 
presence of mutant huntingtin and mitochondrial dys-
function is still unsettled,
20 coenzyme Q10 (CoQ10), an 
essential cofactor of the electron transport system, was 
clinically tested in HD in several centers. However, a 
recently completed large-scale double-blind, randomized, 
placebo-controlled clinical trial of CoQ10 (at 300 mg 
twice daily) concluded that there was no significant 
slowing of functional decline in patients with early 
HD.
21
Another therapeutic candidate for energy crisis is 
“creatine”. Creatine is a substrate for the enzyme 
creatine kinase and can protect vulnerable neurons from 
degeneration through ATP generation.
22 Since a rather 
large dose of creatine administered to HD patients was 
well tolerated and resulted in reduction of serum 
8-hydroxy-2’deoxyguanosine level, an indicator of 
oxidative stress,
23 long-term clinical trials are warranted 
indeed.
3. Anti-apoptosis therapy
In a mouse model of HD, minocycline, a tetracycline- 
derivative compound, delayed HD disease progression 
through down-regulation of apoptosis-related caspase-1 
and -3, and nitric oxide synthetase activities.
24 Open 
clinical trials of minocycline in HD based on the above- 
mentioned finding revealed a long-lasting beneficial 
effect on HD in terms of both choreic movements and 
psychiatric disorders.
25 Again in the mouse model of 
HD, the endogenous hydrophilic bile acid, tauroursodeoxy- 
cholic acid, resulted in reduction of apoptosis in striatal 
neurons, and improvement in locomotion and sensori-
motor deficits.
26 Although basic research in this field is 
active at present, no results of large clinical studies have 
been reported.
Recently, attention was focused on the antibiotic 
rapamycin due to its anti-aggregate formation and 
neuroprotection (vide infra). In addition, rapamycin was 
found to have anti-apoptotic effect as well.
27 Since 
rapamycin is already used clinically as an immuno-
suppressive agent in the United States, this or related 
analogues are suitable candidates for therapeutic in-
vestigation in HD. 
Restorative/reparative therapies for HD  
1. Neural trophic factors
The brain-derived neurotrophic factor (BDNF) 
localized in the cortico-striatal pathways may be one of 
the targets of mutant huntingtin, and is reduced in the 
HD brain to less than a half of the normal level.
28 
Indeed, mutant huntingtin suppressed the levels of both 
mRNA and protein of BDNF in HD mouse model.
28 
Although the effects of glial cell-line derived 
neurotrophic factor (GDNF), delivered by lentivirus, 
were negative,
29 fibroblast growth factor-2 (FGF-2)
30 and 
ciliary neurotrophic factor (CNTF) were reported to 
induce BDNF-like positive results in HD model.
31 
Further studies are needed including drug delivery 
systems before next phase of clinical trials. Although 
neural trophic factors are not specific in a particular 
disease, they may contribute to neural maintenance and 
survival, and may be therapeutically useful in neuro-
degenerative diseases including HD. 
2. Fetal tissue or primary fetal cell transplantation
Premordial striatal tissue grafting into the striatum of 
ibotenic acid-induced rat HD model was first introduced 
by Isacson et al in 1985,
32 suggesting that grafting can 
result in recovery of the neurotransmitter systems. The 
basic idea was fostered to clinical application, and a 
6-year follow-up study of 5 patients who each received Journal of Clinical Neurology: Vol. 2, No. 4, 2006
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implantation of the ganglionic eminence of the human 
embryo into the head of the caudate nucleus and 
putamen, was presented in 2006.
33 According to this 
study, the transplantation did not result in deterioration 
of chorea, and cognitive performance measured by non- 
timed tests remained stable in 3 out of 5 patients. Two 
patients did not show any beneficial effects. However, 
transplantation using fresh fetal tissues is always limited 
by not only technical but also ethical problems. There-
fore, although the clinical outcome was not dis-
appointing, this line of study will shift to stem cell 
transplantation as discussed below. 
3. Stem cell transplantation
Theoretically, “stem cells” are one of the most hopeful 
tools for radical cure of neurodegenerative diseases 
including HD. It is anticipated that neural stem cells 
from fetal brain or adult brain can differentiate 
effectively into striatal neurons and expand over a long 
period of time. Although fetal brain cells have been 
isolated and maintained in the form of neurospheres, 
attempts to differentiate them into striatal neurons have 
not yet been successful.
34 While it is good news that 
neural stem cells are located in the subventricular zone 
of the adult human brain, their functional role in the 
living brain and their availability for treatment of the 
diseased brain is still unclear.
In this respect, Lee et al
35 demonstrated that intra-
venous administration of human neural stem cells in a 
quinolinic acid-induced HD rat model resulted in 
accumulation of cells in and around the striatal lesion 
and their differentiation not only to glial cells but also 
to neurons as well.
35  Moreover, experimental rats 
exhibited a shift to normal response in apomorphine- 
induced rotation test, and showed reduced striatal 
atrophy compared with the control rats that received 
quinolinic acid injection only. The functional recovery of 
rat behavior and the normalization of brain pathology 
are promising and need to be further confirmed in the 
near future. 
So far, no study has claimed the differentiation of 
embryonic stem cells into striatal neurons, and this 
seems far from clinical application. 
Molecular targets in specific and 
radical therapies for HD
1. Short summary of molecular mechanisms of neural 
degeneration in HD
The HD gene is localized on chromosome 4p16.3 and 
named “interesting transcript 15 (IT15)”. The human and 
murine HD genescontain 67 exons. The CAG repeats are 
located at the region near the 5’-end of the open leading 
frame, which encodes a large protein of 350 kDa, and 
is named “huntingtin”.
4 The number of CAG repeats in 
normal chromosome is around 17, at least less than 34, 
whereas that in HD chromosome is more than 36, 
mostly more than 40. These numbers of CAG repeats 
are unstable and inversely correlate with the age at onset 
and with the severity of symptoms. Since CAG is a 
corresponding codon to glutamine, mutant huntingtin has 
abnormally long glutamine stretch near the N-terminal 
end. Huntingtin protein is ubiquitously expressed 
throughout the central nervous system, including every 
neuron. In the HD brain, small projecting neurons 
located in the caudate and the putamen are most 
vulnerable. However, the mechanism of this selectivity 
is not yet elucidated (vide infra).
As mentioned in the Introduction, HD is an inherited 
disease with autosomal dominant trait. Since the 
phenotypes of rare homozygote patients are almost the 
same as those of heterozygotes, HD may be caused by 
a gain-of-function mechanism. Indeed, the truncated 
mutant huntingtin easily enters the nucleus,
36 aggregate 
to form the β-sheet,
5,37 and recruits many types of 
proteins such as histones, splicosomes,
38 enzymes and 
transcription factors,
39 which are essential for cell 
survival. Therefore, it is possible that the mutant 
huntingtin is at least in part neurotoxic. It is also 
possible that mono- and oligomer of mutant huntingtin 
are much more harmful than aggregates themselves.
6 
Furthermore, recent studies have shown that BDNF 
located in the cortico-striatal pathways may be lost when 
normal huntingtin is suppressed in the adult animal, and 
the loss of BDNF function may contribute in part to the 
striatal neuronal degeneration.
40 Therefore, a loss-of- Ichiro Kanazawa, Therapeutic Strategies in Huntington’s Disease 
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Figure 1. Schematic diagram of molecular targets in “therapeutic
strategies” for HD. The outer square represents a cell (neuron) 
and the interior circle is the nucleus. “hht” indicates huntingtin. 
①~⑧  represent individual processes that could be the 
molecular target in HD therapy in the future. The processes are 
designed to: ① inhibit expression of hht in each cell, ② inhibit 
hht truncation, ③ block transfer of truncated hht into nucleus, 
④  inhibit aggregation formation, ⑤  shift the reaction toward 
histone acetylation, ⑥  enhance clearance of degraded hht 
through autophagy, ⑦  normalize transcriptional dysregulation, 
and  ⑧ promote normal protein folding.
function mechanism may also occur as well in the HD 
brain. 
Fig. 1 is a summary of therapeutic strategies based on 
the understanding of molecular mechanisms of neuro-
degeneration happened in HD brain.
 
2. Inhibition of truncation of huntingtin
As mentioned above, the very first step of neuro-
toxicity of mutant huntingtin is truncation of huntingtin, 
which occurs in the cytoplasm by caspase-2,-3,-6, 
calpain and/or aspartic endopeptidase. Since there is no 
specific inhibitor to date against the latter two enzymes, 
only caspase inhibitors (z-VAD-fmk and z-DEVD-fmk) 
have been tested. These inhibitors blocked cleavage of 
huntingtin and subsequently reduced cytotoxicity.
41 
Recently caspase-3- and -6-resistant huntingtin gene- 
containing YAC expressing mice were generated. 
Interestingly, behavior and brain pathology in these mice 
were reported to be less severe in caspase-6-resistant 
mice than wild type.
42 However, caspase does not only 
cleave huntingtin but also many other proteins including 
those protecting cells from degeneration. Therefore, it 
may be extremely difficult to find a therapeutic window 
even at the pre-clinical phase.
3. Inhibition of aggregate formation
Soon after the causal gene was identified and just 
before the nuclear inclusion body was identified, 
transglutaminase drew attention as a candidate patho-
genic factor that interfere with the normal functions of 
cellular proteins, due to its molecular cross-linking 
activity.
43 After wide acceptance of the importance of 
the aggregates, much more attention was paid to this 
enzyme. Particularly, Chun et al
44 demonstrated that 
transglutaminase specifically interacts with a truncated 
form of mutant huntingtin. Indeed, intraperitoneal 
injection of cystamine, a transglutaminase inhibitor that 
is converted to the potent antioxidant cysteamine in 
vivo, in transgenic mouse model of HD resulted in 
improvement of survival rate and reduction of tremor- 
like abnormal movements.
45 Moreover, PET imaging and 
histological studies of HD mouse model after cystamine 
treatment demonstrated the beneficial effects of cystamine 
not only in reduction of aggregates but also in protection 
against striatal neuronal death.
46
As discussed briefly above, one question is not yet 
settled are intraneuronal aggregates/inclusion bodies 
harmful to cell survival; conversely, are they protective 
for cell death by sequestering harmful free forms of 
mutant huntingtin molecule? Interestingly, the same 
research group presented data in support of the former 
concept in one publication, and supported the latter 
concept in the another.
47,48 Nevertheless, many studies 
identified small moleculesas potential polyglutamine 
aggregation inhibitors through screening systems.
47, 49-51 
Indeed. Nukina et al
51 from RIKEN reported that trehalose, 
a popular disaccharide, was one candidate inhibitor of 
polyglutamine-mediated protein aggregation, and actually 
reduced symptoms of HD mouse model. Similarly, 
Congo red binds to the β-sheet structure and inhibits 
polyglutamine oligomerization.
52 Several other compounds 
such as CHIP,
53 Y-27632,
50 PGL-135,
54 Juglone and Journal of Clinical Neurology: Vol. 2, No. 4, 2006
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Figure 2. The relative amount of huntingtin (normal and 
expanded) expressed in 10 single neurons obtained from one 
HD patient. Putaminal neurons and Purkinje cells are analyzed 
because the former are the most severely affected, and the latter 
least affected. A single neuron was dissected from a freeze- 
dried brain tissue of HD patient, using an Eximer-Laser- 
Microdissector. Total amount of mRNA in a single neuron was 
processed quantitatively by RT-PCR, in order to keep the
relative amounts of normal and mutant huntingtin and to
amplify them in the form of cDNA. The amplified cDNAs were 
electrophoresed and densitometrically quantitated. When
comparedwith least affected Purkinje cells, most vulnerable 
putaminal neurons expressed relatively more expanded
huntingtin than normal sized huntingtin. This subtle but definite 
difference in the relative amount of expressed huntingtin 
(normal and mutant) might explain the neuronal selectivity in 
HD brain pathology, and more importantly, might provide an 
excellent hint for a molecular target in HD.
Data shown are unpublished results of experiments conducted 
by Dr. Jeoung Seon-Yong, a brilliant post-doctoral fellow in my 
CREST team (1996-2001). 
Celastrol
55 are under investigation both in vitro and in 
vivo, though no solid results have yet been published.
The truncated huntingtin was demonstrated to interact 
with heat shock proteins, Hsp40 and Hsp70, in hun-
tingtin-expressing cultured cells in a polyglutamine chain 
length-dependent manner. This means that these 
molecular chaperones may be effective in suppressing 
huntingtin aggregation.
56 Since the anti-cancer drug, 
geldanamycin, is known to bind specifically to 
chaperone Hsp90 and to inhibit its chaperone function,
57 
Wanker’s group in Germany applied geldanamycin at 
nanomolar concentrations to huntingtin-expressing cultured 
cells and found that geldanamycin induced Hsp40, Hsp70 
and Hsp90 and suppressed aggregate formation.
58 In 
addition, chaperone manipulation by geldanamycin in 
mice model delayed aggregate formation for one week.
59 
Thus, pharmacological induction of chaperones seems to 
be subtle, but worth further investigation. 
 
4. Normalization of transcriptional dysregulation
Just after the causal gene of HD was identified in 
1993, Gerber et al pointed out that based on the 
existence of the CAG repeat in huntingtin gene, 
huntingtin could interact with transcription factors.
60 
Indeed, recent studies have revealed that mutant 
huntingtin directly interacts with various nuclear 
transcription factors
61 and interferes with the normal 
transcriptional process in vulnerable neurons,
62 
leading to neuronal degeneration. The discovery of 
specific component(s) of the transcription apparatus 
caused by mutant huntingtin using newly developed 
assay system
63 should allow the use of such molecules 
for normalization of the transcriptional dysregulation and 
thus be applied clinically in the future. 
Another approach to the transcriptional dysfunction 
emerged from a study using a Drosophila model of HD. 
Although the transcription processes in cells are 
balanced between histone acetylation and deacetylation, 
this reaction may be shifted to deacetylation catalyzed 
by histone deacetylase (HDAC) in HD model and 
probably in polyglutamine diseases.
64  Correction of this 
shift could be, therefore, a suitable strategy for a novel 
therapy of HD. Indeed, one of the HDAC inhibitors, 
sodium butyrate, was reported to modulate the trans-
cription, significantly enhanced survival, and delayed the 
neuropathological changes in a R6/2 HD mouse model.
65
5. Enhancement of autophagic clearance of ab-
normal proteins
The lipophilic macrolide antibiotic rapamycin was 
recently reported to induce autophagy by inactivating 
“mammalian target of rapamycin (mTOR)” which is a 
type of serine-threonine kinase.
66 Rubinsztein’s group in 
Cambridge, UK, demonstrated that high glucose 
concentrations in cultured cells enhanced clearance 
of mutant huntingtin, together with increased autophagy 
and reduced phosphorylation of mTOR.
67 This line Ichiro Kanazawa, Therapeutic Strategies in Huntington’s Disease 
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Figure 3. (a) A schematic drawing of the construct used in the 
in vitro experiments and target position of siRNA;
siRNA-HDExon1. The constructed expression vector contains 
HD gene exon 1. Cytomegalovirus promoter [P (CMV)] was 
ligated at the 5’ end of exon 1 gene, and a set of the sequence 
for GFP [EGFP] ligated at the 3’end as a reporter. Two groups 
of constructs were used in terms of the length of CAG repeats: 
normal HD exon 1 containing 17 CAG repeats and mutant HD 
exon 1 containing 72 CAG repeats.
79  (b) Nucleotide sequence of 
the siRNA-HDExon1. This sequence was second best in terms 
of “specificity” or “uniqueness” based on BLAST search, but 
best in its “efficacy” on silencing the huntingtin gene.
79
of evidence was also presented in fly and mouse models 
of HD.
68 In contrast to this “rapamycin-related story”, 
Yamamoto et al
69 recently claimed the presence of 
mTOR-independent autophagy in huntingtin-expressing 
cultured cells, and that such autophagy could be 
achieved by insulin-signaling pathway.
69 Although these 
findings are still in the laboratory phase, an enhanced 
clearance of mutant huntingtin is a reasonable direction 
in developing a new therapy for HD. 
6. Specific inhibition of huntingtin gene expression by 
RNA interference 
Although a loss-of-function mechanism may exist, we 
believe that the major mechanism of the striatal neural 
loss is due to a gain-of-function. This concept is 
supported by many studies.
6,36,39,40 If so, as Haque et al
70 
has suggested first, down-regulation of mutant huntingtin 
expression may be a promising therapeutic strategy. This 
concept was strongly supported by a recent publication 
by Yamamoto and colleagues
71 using a conditional mouse 
model of HD. In their study, they demonstrated that 
“switching off” of the transgenic huntingtin expression at 
the adult age lessened the severity of the disease, 
suggesting that HD might be reversible. 
Moreover, we have found in our preliminary single 
neuron analysis that the ratio of mutant to normal 
huntingtin gene expression of the most vulnerable striatal 
remaining neurons in a HD patient was 10-15% more 
than that of Purkinje cells, which are the least affected 
in HD (Fig. 2). It is reasonable to suppose that neurons 
would be killed earlier if a relatively large amount of 
mutant huntingtin is expressed even if the difference is 
subtle. This assumption can also explain the selectivity 
of striatal neuronal death in HD. Therefore, in order to 
formulate a molecular therapeutic strategy for HD, it is 
feasible to suppress the mutant huntingtin expression. In 
this respect, several techniques have already been 
explored to suppress the expression of huntingtin, in-
cluding antisense technology
72,73 and catalytic DNA.
74 
However, these tools have their own problems such as 
instability of the single strand RNA molecule or 
unexpectedly low efficacy. 
In this respect, it is worthy to note that RNA 
interference (RNAi), the process of posttranscriptional 
gene silencing mediated by double-stranded RNAs 
(dsRNAs) first discovered in Caenorhabditis elegans,
75 
has rapidly emerged as an important tool for regulating 
the gene expression in a wide range of species
76 
including mammals. Particularly inmammalian cells, 
inhibition of the specific gene expression is mediated by 
short inhibitory RNAs (siRNAs), which are dsRNAs 
composed of 21-22 nucleotides (nt) with 2 nt overhang 
on 3’ terminus of each strand, whereas dsRNAs longer 
than 30 nt induced a global suppression of the gene 
expression by a mechanism related to interferon 
response.
77,78 Therefore, several studies, including those 
from our laboratories, have started to develop RNAi 
systems designed to suppress huntingtin expression. 
In order to prepare 21 nt RNAs, we first searched 
BLAST through the HD mRNA and found two sites that 
have unique sequences as valid targets of siRNA 
siRNA-5’UTR in 5’ untranslated region and siRNA- 
HDExon1 in ORF at immediate upstream of CAG repeats. 
Comparison of the silencing effects of these two siRNAs 
using cultured cells showed that siRNA-HDExon1 is 
much stronger than the other.
79 Indeed, the lowest 
concentration of the effective siRNA-HDExon1 to Journal of Clinical Neurology: Vol. 2, No. 4, 2006
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Figure 4. Fluorescence images of COS-7 cells transfected with 
construct ligated with EGFP shown in Fig. 3. Upper panel (a): 
cells transfected with the construct inserted with HD exon 1 
containing normal sized 17 CAG repeats. Lower panel (b): cells 
transfected with the construct inserted with HD exon 1 
containing mutant sized 72 CAG repeats. Left columns: cells 
transfected with HD gene construct alone. Right columns: cells 
co-transfected with HD gene construct and siRNA-HDExon1 
(40 nM). Note that cells transfected with the construct of 
mutant sized CAG repeats exhibit intracellular aggregation 
formation. In addition, note that HD gene is strongly suppressed 
in siRNA co-transfected cells compared with cells without 
siRNA.
79
Figure 5. A mouse (R6/2) model of HD generated by Bates 
et al in 1996 and purchased from Jackson Laboratory. Brains 
from 8-week-old mice were immunostained with antibody 
against mutant huntingtin (MAB5374) that recognizes the 
N-terminal portion of this human protein. Note the abundant 
presence of neuronal intranuclear inclusions of mutant 
huntingtin in the striatum of mock-treated and untreated 
mice, and in contrast, a clear decrease in the number of 
cells with intranuclear inclusions in the striatum of 
siRNSHDExon1-treated mice. Scale bar: 200 μm for the 
upper panel (magnification x40) and 30 μm for the 
lower panel (magnification x100).
80
Figure 6. Effects of siRNA-HDExon1 on the survival rate of 
R6/2 mice model of HD. Kaplan-Meier survival curves showing 
that siRNA-HDExon1 treatment significantly extended the longevity 
o f  R 6 / 2  m i c e  ( p<0.0001 by log-rank test, siRNA-treated, n=39; 
mock-treated, n=9; untreated, n=65). Wild-type mice that had 
received sham treatment had a normal lifespan (data not 
shown).
80 
suppress huntingtin gene expression in COS-7 cells was 5 
nM.
79 The nucleotide sequence of the siRNA-HDExon1 
is shown in Fig. 3, and its effect at 40 nM is shown in 
Fig. 4. Since other genes such as β-actin and GAPDH 
were not altered, siRNA-HDExon1 specifically suppresses 
the expression of huntingtin gene.
79 At this stage, these 
studies are ready to move to the in vivo experiment.
SiRNA-HDExon1 was introduced intraventricularly 
into a R6/2 mouse model of HD on the second day after 
birth. The injected siRNA-HDExon1 inhibited transgenic 
huntingtin expression in brain neurons and reduced the 
number and size of intranuclear inclusions in striatal 
neurons (Fig. 5). More importantly, siRNA treatment 
significantly prolonged longevity (Fig. 6), improved 
motor function, and slowed down the loss of body 
weight.
80
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designed toward silencing the huntingtin gene were 
reported by other groups.
71-83 However, these reports are 
different from our results at least with regard to the 
following three points; 1. nucleotide sequences of 
dsRNA used were different. 2. short hairpin RNA 
(shRNA) was used, instead of straight siRNA, in order 
to stably and constantly produce siRNA in cells. 3. those 
shRNAs were ligated to vectors of adeno-associated 
virus (AAV), instead of naked siRNA. 
In May 2006, an important study was published in 
Nature, which reported that administration of shRNAs 
with AAV vectors to produce long-term suppression of 
the target gene could interfere with the normal function 
of endogenous microRNAs. This may be due to 
oversaturation of endogenous microRNA/exogenous 
shRNA pathways in which both RNA molecules use the 
same components of RNAi apparatus.
84 Potential 
problems that could also occur in RNAi were also 
recently pointed out by Aronin.
85 We strongly intended, 
from the very first step of our study, to avoid 
unexpected and uncontrollable adverse events in 
volunteer patients. Therefore, it is important to develop 
a “transient” suppression system of huntingtin gene as 
we did, instead of long-term suppression. Since the rate 
of expression of AAV-delivered shRNA in cells can not 
be controlled, I absolutely prefer to use siRNA that will 
remain only transiently inside the cells, even if siRNA 
should be delivered directly into the striatum or 
ventricles of HD patients.
Finally, the result of an interesting study should be 
mentioned here, which was based on the understanding 
of HD as a disease of metal abnormality. Indeed, 
Nguyen et al
86 have applied the metal-binding compound 
clioquinol to R6/2 mouse model of HD and revealed 
almost the same level of clinicopathological beneficial 
effects. It is, therefore, important to screen available 
chemicals as many as possible, in order to find 
beneficial effects in animal models of HD, and hopefully 
in human. 
CONCLUSIONS
In 1972, almost 100 years after the first description of 
HD by George Huntington, a GABA deficiency in HD 
brain was discovered. In 1983, nearly 10 years after that, 
a localization of HD gene was found at the short arm 
of the chromosome 4. Furthermore, in 1993, exactly 10 
years after that, the causal gene of HD was finally 
identified. From analogy to this previous history of HD 
research, we hoped that in 2003, 10 years after the 
identification of the HD gene, a radical treatment could 
be clinically realized. Unfortunately, this is not the case. 
However, I am pleased to know that from around 2003 
we can discuss about “therapeutic strategies” for HD 
with reality. Although we have a long way to go in 
developing an actual radical treatment for HD, I hope 
that the novel strategies including a stem cell therapy 
and/or a gene silencing therapy could reach to the level 
of clinical trials in near future.
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